Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Historical Article
  • Authors:
    Roddie C, Peggs KS
  • Publication date:
  • Pagination:
    473, 487
  • Journal:
    Expert Opin Biol Ther
  • Volume:
  • Issue:
  • Status:
  • Country:
  • Language:
  • Keywords:
    Adult, Animals, Child, Graft vs Host Disease, Graft vs Tumor Effect, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, History, 20th Century, Humans, Lymphocyte Transfusion, Neoplasm, Residual, Secondary Prevention, T-Lymphocytes, Regulatory, Tissue Donors, Transplantation, Homologous, Treatment Outcome
INTRODUCTION: Allogeneic hematopoietic stem cell transplantation (SCT) is the treatment of choice for many malignant hematological disorders. Following recent improvements in non-relapse-related mortality rates, relapse has become the commonest cause of treatment failure. Infusion of donor lymphocytes can potentially enhance immune-mediated antitumor activity and offers a salvage option for some patients. This paper reviews the current literature on the efficacy of this therapeutic strategy. AREAS COVERED: The biology of adoptive cellular therapy with allogeneic immune cells to treat relapse across a spectrum of diseases in both the full intensity and reduced intensity hematopoietic SCT settings is explored. The review discusses the current limitations of the approach and reviews several new experimental strategies which aim to segregate the desired graft-versus-tumor effect from the deleterious effects of more widespread graft-versus-host reactivity. EXPERT OPINION: Durable responses to DLI have been noted in chronic myeloid leukemia and responses have also been described in acute leukemia, multiple myeloma and chronic lymphoproliferative disorders. The new challenge in transplantation is to optimize DLI therapy in order to further improve patient outcomes.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Research Department of Haematology
Cancer Institute
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by